Our results in the murine tumor model demonstrated that combination therapy exhibited the greatest antitumor effects and prolonged survival compared to control, MSLN-CAR T cells, and HSV-MSLN monotherapies (Fig. 4). Here, MSLN is linked to neoplasm.